Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]
News [12658]
Articles [175]
Editorials [5]
Conferences [248]
elearning [17]
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma
Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )
4 Jun 2012
Increased risk of breast cancer among young women treated with radiation as a...
Dr Chaya Moskowitz - Memorial Sloan-Kettering Cancer Center, New York, USA
Increased risk of breast cancer among young women treated with radiation as a child ( Dr Chaya Moskowitz - Memorial Sloan-Kettering Cancer Center, New York, USA )
4 Jun 2012
New MEK inhibitor, trametinib, improves survival in advanced melanoma
Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France
New MEK inhibitor, trametinib, improves survival in advanced melanoma ( Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France )
4 Jun 2012
Afatinib delays progression of advanced lung adenocarcinomas
Dr James Yang - National Taiwan University Hospital, Taipei
Afatinib delays progression of advanced lung adenocarcinomas ( Dr James Yang - National Taiwan University Hospital, Taipei )
4 Jun 2012
Costly drugs versus paclitaxel as first line therapy for locally advanced or...
Dr Hope Rugo - University of California San Francisco, USA
Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, USA )
4 Jun 2012
Regorafenib effective for GISTs that progress due to resistance to approved...
Dr George Demetri - Dana Farber Cancer Institute, Boston, USA
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana Farber Cancer Institute, Boston, USA )
4 Jun 2012
EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2...
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA
EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )
3 Jun 2012
Increased progression-free survival in advanced lung cancer with afatinib
Dr James Yang - National Taiwan University Hospital Taipei, Taiwan
Increased progression-free survival in advanced lung cancer with afatinib ( Dr James Yang - National Taiwan University Hospital Taipei, Taiwan )
3 Jun 2012
Intermittent hormonal therapy versus continuous therapy for advanced prostate...
Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012
Changing the standard treatment for lymphoma with bendamustine
Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany
Changing the standard treatment for lymphoma with bendamustine ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )
3 Jun 2012
Trastuzumab emtansine improves progression-free survival for HER2-positive...
Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA
Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )
3 Jun 2012
Continuing bevacizumab with second-line chemotherapy for colorectal cancer
Dr Dirk Arnold - University Cancer Center Hamburg, Germany
Continuing bevacizumab with second-line chemotherapy for colorectal cancer ( Dr Dirk Arnold - University Cancer Center Hamburg, Germany )
3 Jun 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation